Pancreatic Cancer Awareness Month

‍ ‍

This November, during Pancreatic Cancer Awareness Month, we’re reflecting on where new hope is emerging in one of the hardest cancers to treat.
About 90% of pancreatic cancers carry a mutation called KRAS -  a change that helps tumours grow and spread without any restrictions.
At Celex Oncology Innovations Ltd, our research focuses on voltage-gated sodium channels (VGSCs) - molecules that sit upstream of KRAS and influence how aggressive cancer cells become.
Let’s take a look at what our CEO Carsten Faltum says about why new treatment methods are needed.
 By understanding and targeting these early drivers of tumour behaviour, we aim to help pave the way for future approaches that may one day slow or better manage the spread of pancreatic cancer.
Because when you decode how cancer is progressing, you can start to control it.

‍ ‍